Tandem Diabetes Care: Pay

Tandem Diabetes Care paid its 5 named executives $14.7M in total in FY2025 (Dec). CEO John Sheridan was paid $6.9M of that.

Pay$100 in the stock at the end of FY20 → $23
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

John SheridanPresident and Chief Executive Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)Not disclosed
FY2021 (Dec)Not disclosed
5 years
Mark NovaraExecutive Vice President, Chief Commercial Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)Not disclosed
3 years
Leigh VossellerExecutive Vice President, Chief Financial Officer and Treasurer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)Not disclosed
FY2021 (Dec)Not disclosed
5 years
Elizabeth GasserExecutive Vice President, Chief Strategy and Product Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)Not disclosed
FY2021 (Dec)Not disclosed
5 years
Shannon HansenExecutive Vice President, Chief Legal, Privacy and Compliance Officer and Secretary
FY2025 (Dec)
1 year

CEO pay against the pay peers

In FY2025 (Dec), the median CEO pay of the 9 peers with pay on file was $7.7M. CEO pay of Tandem Diabetes Care for that year is not on file.

  1. 1Insulet
  2. 2GLAUKOS
  3. 3QuidelOrtho
  4. 4AtriCure
  5. 5Inspire Medical Systems
  6. 6CONMED
  7. 7Staar Surgical
  8. 8Artivion
  9. 9Globus Medical
  10. 10Tandem Diabetes CareNot disclosed
  11. 11AngioDynamicsNot disclosed
  12. 12DexcomNot disclosed
  13. 13HaemoneticsNot disclosed
  14. 14ICU MedicalNot disclosed
  15. 15InogenNot disclosed
  16. 16LivaNovaNot disclosed
  17. 17MasimoNot disclosed
  18. 18NevroNot disclosed
  19. 19iRhythm TechnologiesNot disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.